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Abstrae!: The lour stereoisomers 01 methyltetrahydroluran-2-ylmethyl 2.6-dimethyl-4-(0-nitrophenyl)-l,4-dihydro-
pyridine-3,5-dicarboxilate (furnidipine), have been synthesized and separated by chiral chromatography using
D-phenylglycine as chiral stationary phase. Enantiomeric purity 01 stereoisomers is determined by HPLC-CSP
technique and configurations deduced via X-ray crystallography.
The 4-aryl-l ,4-dihydropyridines1 first prepare<! by Hantzsch2 have attracted substantial attention since the discovery
of their calcium antagonists properties.3 Their subsequent therapeutical applications has led to an enormous effort being
devoted to the clinical development of new derivatives. The symmetrically substituted dimethyl 2.6-dimethyl-4-(o-nitro-
phenyl)-1,4-dihydropyridine-3.S-dicarboxylate (Nifedipine) was the first l,4-dihydropyridine used clinically against angina
pectoris and hypertension.4 More recent pharmacological studies on other members of this class of drugs has shown that
the enantiomers of chiral 1,4-dihydropyridines such as nimodipine and nicardipine exhibited not oniy activities
quantitatively different but also qualitatively.5 Moreover, there are even examples in which both enantiomers have the
opposite action profile with one of the enantiomers being a calcium antagonist and the other one a calcium agonist In
view of the great importance of chirality 10 pharmacological activity in these drugs. the separation of enantiomers or the
development of stereoselective syntheses is of great interest for obtaining new and more selective molecules with
therapeutical applications.6
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1 (Fumidipine)R' = R2= Me ; R3= 2"NC:l:!(Nifedipine)
R' = i-Pr; R2= CH¡:HpMe ; R3= 3-NO" (Nimodipine)







As result of a screening by Cermol S.A. laboratories of the calcium antagonist activity of numerous 4-aryldihydro-
pyridine-3.5-dicarboxilates we have found that methyl tetrahydrofuran-2-ylmethyl 2.6-dimethyl-4-(o-nitrophenyl)-1,4-
dihydropyridine-3.5-dicarboxylate 1 (furnidipine), is a new, highly active and specific calcium antagonist. This
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dihydropyridine derivative is also a chira! structure and exists as four stereoisomers, alI of them needed in
enantiomericalIy pure form for pharmacological studies direcled lo determine possible activity differences.
OplicalIy active 1,4-dihydropyridines have been prepared either by chemical or enzymatic resolution of the
racemates or by chira! chromatographic separation of the antipodes.7 The preparation of pure four stereoisomers of 1
was first attempted by adapting the method reported by Shibanuma and co-workers8 with the acid
4 by resolution of 5-methoxycarbonyl-2,6-dimethyl-4-(o-nitrophenyl)-1 ,4-dihydropyridine-3-
carboxylic acid 3 and esterification of the acid with enantiomeric pure tetrahydrofurfuryl alcohol.
The process however, fai1ed because the o-nitro group facilitates the oxidation of the
dihydropyridine moiety. the product being the pyridine derivative isolated under different
conditions. A similar process has been described for nifedipine itself and severa! 2-nitrophenyl
derivatives5.
The possibility of preparing the enantiomericalIy pure acid from unsymmetricalIy
substituled l,4-dihydropyridines oblained by asymmetric synthesis was also considered but
discarded since nifedipine analogues bearing 2-nitropheny1 substituents on C-4 have not been prepared in enantiomericalIy
pure form in the two previously reponed asymmetric syntheses of chira! dihydropyridines.9•10 Therefore, we decided lO
develop a method based on separation of covalent diastereomers.
The simple synthetic route stans with commercialIy available racemic tetrahydrofurfuryl alcohol 5 which was
lransformed 10 the racemic acid with lones's reagent and the acid resolved following the method described by Belanger
and col.1l ESlerification of the enantiomeric acids gave the esters which were reduced with NaBH4 furnishing (S)- and
(R)-tetrahydrofurfuryl alcohols.12•13Funher elaboration into diaslereomeric furnidipine la and lb via a modified Hantzsch
synthesis14,15 is shown in Scheme 3. In both possible routes la and lb were obtained as a (50:50) mixture of
diastereomers and no diastereomeric excess was detected under different conditions.
The separation of diaslereomers was carried Oulby chira! preparative HPLC using a Pirkle column (250 x 30 mm
Ld.) packed with D-phenylglycine.16 Samples (0.5 mI) were injected as solutions in the eluent (dichIoromethane) at a flow
rate of 22 m1/min and detecled by absorbance at 254 nm. In a typical separation a dichIoromethane solution of
furnidipine la (c=80 mg/mI) afforded four fractions (F1-F4 in Figure 1) which after being rechromatographed (twice for
F3) gave pure diaslereomers (>99% d.e.).
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Agure 1. Analy1ical chromatDgram frem!he chiral HPlC 01a mixture 01R,5-1 and S,5-1 on a Pirkle
column (250 x 4.6 mm i.d.). Samples (20 ¡!l, e 0.1 mg/ml) were injected in dichlorometane as a flow rate 01
1.5 mllmin and detected by absorbance at 335 nm.
The enantiomeric purity of the four stereoisomers of 1 (Scheme 3) was also determined by HPLC-CSP by using
an (ll-acid glycoprotein column17 (100 x 4.6 mm Ld.) with H20/i-PrOH (9:1) as eluent and a flow rate of 0.2 m1/min.
A 20 ¡ll injecled sample (e=0.1 mg/ml) detecled by absorbance al 335 nm gave retention times belween 24 and 32 min
for the stereoisomers.
Synthesis of the stereoisomers of furnidipine 619
6b
7b
(1) 1>98% 991 \. 98%VIII \
1 1 95%99 1 (1)





















(1) 1>98%9.91 I\"H1>98% 9.91 (1) ,,_,,>VoH
~ ~a
O IV,V 64% 5a





1> 99% d.9·1 (2)
I 99% e.e. 1 (3)
R,R-1
(2) 1>99%d.9.j
(3) 1 94% 9.9.
S,R·1
1> 99% d.9.j (2)
I 94% 9.9. j(3)
Scheme 3. Simplified synthesis of fumidipine. i)Jones's reagent, acetone, O °C; ii) For resolution of the acid and
ester formation see ref. 9; iii) NaBH4, EtOH, reflux; iv) 2,2,6-Trimethyl-l,3-diox-5-en-4-one, xy1ene, reflux;
v) 2-02N-C6H4-CHO, i-PrOH, piperidine, AcOH, 40oC; vi) H4WAcO-,EtOH, reflux; vii) H2N(H3C)C=CHC02CH3,
i-PrOH,reflux, N2, proteeted from light; viii) 2-02N-C6H4CH=C(C02CH3)COCH3' i-PrOH, reflux, N2, proteeted from
light; ix) Chira! chromatographic separation.
(1) Determined by lH_NMR analysis with Eu(hfc)3; (2) Determined by HPLC-CSP (Pirlde co1umn, see text);
(3) Determined by HPLC-CSP (a¡-acid glycoprotein column, see text).
620 R. ALAJARIN et al.
The assigned configurations were determined
by subjecting a crystal of racemic fumidipine 1
purified by fractional crystallization lO X-Ray
diffraction analysis (Figure 2). The racemate
(R,RIS,S)-1 crystallizes in the triclinic system P-I
with unit cell dimensions a=8.127(1), b=1O.603(1),
c=25.506(3) A, a=99.819(1)o, 8=90.477(1)°,
y=109.151(1)o, V=2042.93 A3, Z=2, Dc=1.355
g/cm3, F(OOO)=880~(MoKa)= 0.959 cm-l. The final
R value was 0.155. The structure was assigned by
X-Ray single-crystal analysis based on intensity data
collected (1551 reflections) with a Nonius CAD-4
automatic four-circle diffractometer.18
Figure 2. Stereoscopic view of (R,RlS,S)-1
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